![Erik Emerson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erik Emerson
Directeur Général chez
GLUCOTRACK, INC.
Fortune : 458 612 $ au 31/08/2026
Profil
Mr. Erik Emerson is a Chief Executive Officer & Director at GlucoTrack, Inc. and a Chief Executive Officer & Director at Lokahi Therapeutics, Inc. He is on the Board of Directors at GlucoTrack, Inc. and Lokahi Therapeutics, Inc. Mr. Emerson was previously employed as a President & Director by Apimeds Pharmaceuticals US, Inc., a Chief Commercial Officer by Odyssey Health, Inc., a Chief Commercial Officer by Mezzion Pharmaceuticals, Inc., a President & Chief Executive Officer by Symplmed Pharmaceuticals LLC, a Senior Director-Commercial Development by XOMA Corp., and a Marketing Director by Gilead Sciences, Inc. He also served on the board at Adhera Therapeutics, Inc. He received his undergraduate degree from the University of Oregon.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
4,97 % | 15/10/2025 | 75 000 ( 4,97 % ) | 291 000 $ | 31/08/2026 |
GLUCOTRACK INC 4,94 % | 10/08/2026 | 39 438 ( 4,94 % ) | 167 612 $ | 31/08/2026 |
Postes actifs de Erik Emerson
| Sociétés | Poste | Début |
|---|---|---|
| GLUCOTRACK, INC. | Directeur Général | 14/07/2026 |
Anciens postes connus de Erik Emerson
| Sociétés | Poste | Fin |
|---|---|---|
| ODYSSEY HEALTH, INC. | Corporate Officer/Principal | 01/10/2023 |
Mezzion Pharmaceuticals, Inc.
 Mezzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug manufacturing company | Corporate Officer/Principal | 01/01/2020 |
| ADHERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 19/12/2019 |
Symplmed Pharmaceuticals LLC
 Symplmed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur Général | 01/05/2018 |
Formation de Erik Emerson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
55
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
GlucoTrack, Inc.
 GlucoTrack, Inc. Medical SpecialtiesHealth Technology Develops a non-invasive glucose monitoring device | Health Technology |
Odyssey Health, Inc.
 Odyssey Health, Inc. Medical SpecialtiesHealth Technology Develops heart monitoring and screening devices | Health Technology |
University of Oregon
 University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adhera Therapeutics, Inc.
 Adhera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes hypertensive drugs | Health Technology |
Symplmed Pharmaceuticals LLC
Symplmed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Mezzion Pharmaceuticals, Inc.
Mezzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug manufacturing company | Health Technology |
